Morgan Stanley
IMMX icon

Morgan Stanley’s Immix Biopharma IMMX Stock Holding History

Morgan Stanley’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
139,886
+13,264
+10% +$97.4K ﹤0.01% 5024
2025
Q4 		$662K Buy
126,622
+5,952
+5% +$24.5K ﹤0.01% 5374
2025
Q3 		$252K Sell
120,670
-4,249
-3% -$10.2K ﹤0.01% 5801
2025
Q2 		$259K Buy
124,919
+42,627
+52% +$85.8K ﹤0.01% 5748
2025
Q1 		$138K Sell
82,292
-8,759
-10% -$16.5K ﹤0.01% 5875
2024
Q4 		$200K Buy
91,051
+6,738
+8% +$12.3K ﹤0.01% 5785
2024
Q3 		$126K Buy
84,313
+25,856
+44% +$52K ﹤0.01% 5909
2024
Q2 		$116K Buy
58,457
+4,412
+8% +$10.1K ﹤0.01% 5912
2024
Q1 		$166K Buy
54,045
+21,709
+67% +$84.1K ﹤0.01% 5789
2023
Q4 		$224K Buy
32,336
+31,936
+7,984% +$145K ﹤0.01% 5896
2023
Q3 		$1.37K Buy
+400
New +$938 ﹤0.01% 7191
2023
Q1 		– Sell
-1
Closed -$2 – 7770
2022
Q4 		$2 Sell
1
-2
-67% -$3 ﹤0.01% 7856
2022
Q3 		$0 Buy
+3
New +$7 ﹤0.01% 7790

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Morgan Stanley's IMMX Position: Q1 2026 in Review

Morgan Stanley increased its Immix Biopharma (IMMX) stake by 10% in Q1 2026, buying an estimated $97.4K and bringing the position to 139,886 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #5024.

Morgan Stanley first reported a position in IMMX in Q3 2022 and has held it in 13 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Morgan Stanley held 139,886 shares of Immix Biopharma worth $1.27M as of Q1 2026.
  • Morgan Stanley bought 13,264 Immix Biopharma shares in Q1 2026, an estimated $97.4K.
  • Immix Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5024 holding.
  • Morgan Stanley first reported a position in Immix Biopharma in Q3 2022 and has held it in 13 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.